CRSP

In Q4 2025, CRISPR Therapeutics reported strong Casgevy revenue, leading to positive stock movement. In March 2026, the company announced a convertible senior notes offering, which can lead to short-term stock price adjustments. In Q1 2026, CRISPR Therapeutics reported a wider-than-expected loss per share, but the stock gained due to commercial progress for Casgevy and a strengthened cash position. Analysts have maintained a generally positive outlook, and ARK Investment Management and UBS Group increased their stakes. News of a competing sickle cell stock receiving approval could introduce competitive pressures.